1-benzyl-2-(pyridin-2-yl-methyl)-1H-benzoimidazole | 1208449-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-benzyl-2-(pyridin-2-yl-methyl)-1H-benzoimidazole
• 英文别名: 1-Benzyl-2-(2-pyridylmethyl)benzimidazole；1-benzyl-2-(pyridin-2-ylmethyl)benzimidazole
• CAS: 1208449-32-4
• 化学式: C₂₀H₁₇N₃
• 分子量: 299.375
• InChiKey: WNUBNVJNMRSULA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 溶剂黄146 作用下， 反应 5.0h， 生成 1-benzyl-2-(pyridin-2-yl-methyl)-1H-benzoimidazole
  参考文献：
  名称：

  Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus

  摘要：

  A series of novel benzimidazole derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activity and cytotoxicity in the HepG2.2.15 cell line. The preliminary SAR was discussed. Compound 12a, with IC50 < 0.41 mu M and SI > 81.2, was the most promising compound and selected as the benchmark compound for further optimization. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.076

文献信息

• MIF MODULATORS
  申请人：Jorgensen William L.

  公开号：US20120040974A1

  公开（公告）日：2012-02-16

  The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

  该发明提供了新型杂环化合物、制药组合物和治疗方法，可调节MIF表达水平并治疗与高或低MIF表达水平有关的疾病。
• MIF modulators
  申请人：YALE UNIVERSITY

  公开号：US10202343B2

  公开（公告）日：2019-02-12

  The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

  本发明提供了新型杂环化合物、药物组合物和治疗方法，可调节 MIF 的表达水平，治疗与 MIF 表达水平过高或过低有关的疾病。
• MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION
  申请人：MIFCARE

  公开号：US20170079958A1

  公开（公告）日：2017-03-23

  The present invention relates to the use of compounds of general Formula I and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.
• US9540322B2
  申请人：——

  公开号：US9540322B2

  公开（公告）日：2017-01-10
• US9643922B2
  申请人：——

  公开号：US9643922B2

  公开（公告）日：2017-05-09